Soy isoflavones reduce asthma exacerbation in asthmatic patients with high PAI-1-producing genotypes.

ABSTRACT:

Background

The 4G4G genotype of plasminogen activator inhibitor 1 (PAI-1) is associated with increased plasma PAI-1 levels and poor asthma control. Previous studies suggest that soy isoflavones can reduce PAI-1 levels.

Objective

We sought to investigate PAI-1 genotype-specific differences of the soy isoflavone response in asthma outcomes.

Methods

A PAI-1 functional polymorphism (rs1799768, 4G5G) was characterized in subjects with poorly controlled asthma enrolled in a randomized clinical trial of soy isoflavones (n = 265). Genotype-specific treatment responses on asthma outcomes were compared between soy isoflavones and placebo. Normal human bronchial epithelial cells were cultured with or without TGF-β1, genistein, or both, and PAI-1 levels were measured.

Results<

SUBMITTER: Cho SH 

PROVIDER: S-EPMC6612283 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature